At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 277 enrolled
Drug / intervention
Everolimusdrug
Likely dose
Everolimus 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Everolimus (RAD001) in Relapsed/Refractory Lymphoma
In Brief
A Phase 2 clinical trial evaluating Everolimus for Leukemia and 2 related conditions. Completed, enrolled 277 participants across 3 sites.
Detailed Summary
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. PURPOSE: This phase II trial is studying the side effects and how well everolimus works in treating patients with lymphoma that has relapsed or not responded to previous treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Lymphoma, Lymphoproliferative Disorder
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2005
First PostedFeb 2007
Primary CompletionDec 2010
Study CompletionOct 2019
TodayJul 2026
First PostedFeb 19, 2007
Enrollment StartAug 1, 2005
Primary CompletionDec 1, 2010
Study CompletionOct 9, 2019
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 19.4 years ago
Interventions
Everolimusdrug
Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.